(NASDAQ: RYTM) Rhythm Pharmaceuticals's forecast annual revenue growth rate of 58.91% is not forecast to beat the US Biotechnology industry's average forecast revenue growth rate of 64.17%, and while it is forecast to beat the US market's average forecast revenue growth rate of 10.07%.
Rhythm Pharmaceuticals's revenue in 2025 is $130,126,000.On average, 11 Wall Street analysts forecast RYTM's revenue for 2025 to be $11,591,311,661, with the lowest RYTM revenue forecast at $11,236,120,762, and the highest RYTM revenue forecast at $12,164,245,075. On average, 11 Wall Street analysts forecast RYTM's revenue for 2026 to be $19,173,606,792, with the lowest RYTM revenue forecast at $15,838,175,851, and the highest RYTM revenue forecast at $25,289,490,800.
In 2027, RYTM is forecast to generate $34,542,662,589 in revenue, with the lowest revenue forecast at $26,640,645,070 and the highest revenue forecast at $41,355,272,068.